Francesco Zaja

36PUBLICATIONS
131CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Sep 16, 2026
Real-World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST-CLL Study.

|Mar 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Stefano Molica, Potito Rosario Scalzulli, Lydia Scarfò

|Jan 28, 2026
Key Indications for Passive Immune Prophylaxis Against SARS-CoV-2 Infection in Malignant Hematological Disorders: An Analytic Hierarchy Process by an Ad Hoc Italian Expert Panel.

Monia Marchetti, Giovanni Barosi, Francesco Passamonti

|Sep 19, 2025
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.

Andrea Visentin, Enrico Gaffo, Moritz Fürstenau

|Jun 25, 2025
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.

Sara Pepe, Candida Vitale, Diana Giannarelli

|Jan 25, 2025
A New Antibody-Cytokine Construct Targeting Natural Killer Cells: An Immunotherapeutic Approach to Chronic Lymphocytic Leukemia.

Michela Flego, Mauro Andreotti, Francesca Romana Mauro

Pageof 6

Frequent Collaborators

12 joint publications

Luca Laurenti

12 joint publications

Andrea Visentin

10 joint publications

Gianluigi Reda

9 joint publications

Paolo Sportoletti